Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MENDEL-2: Evolocumab Monotherapy in Hyperlipidemia
NCT01763827Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2013
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of evolocumab in hyperlipidemia, sponsored by Amgen. Started Jan 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT01763827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763827.